catalyst
as of 2026-07-01A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emrac — primary completion
at a glance
2028-02 · Estimated (est.) — Registry-estimated date, not yet actual.
Synthesized from structured facts only — each point cited above.
Event
What
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emrac — primary completion
Type
Trial Readout
Date
2028-02
Date type
ESTIMATED est.
Phase
Phase 2
Registry-estimated date, not yet actual. This date is directional and must not be read as settled.
relationships
The graph out of here